Transgene Biotek

Which are the latest news on Transgene Biotek?

Why is Transgene Biotek Ltd falling/rising?

As of 09-Jun, Transgene Biotek Ltd's stock price is at 3.06, showing a slight increase but overall experiencing a downward trend with a significant decline of -24.63% over the past year, indicating ongoing challenges and decreased investor interest.

As of 09-Jun, Transgene Biotek Ltd's stock price is currently at 3.06, reflecting a change of 0.02 (0.66%) upward. However, the stock has been experiencing a downward trend overall, having underperformed its sector by -1.91% today and showing a consecutive fall over the last three days with a total decline of -3.51% during this period. <BR><BR>In terms of longer-term performance, the stock has seen a significant decline of -24.63% over the past year, which is notably worse than the Sensex's decline of -10.34% in the same timeframe. Additionally, the stock has underperformed against the benchmark in various periods, including a -2.86% year-to-date performance compared to the Sensex's -13.26%. <BR><BR>Investor participation has also decreased, with a delivery volume of 2.69 k on June 8, which is down by -89.05% compared to the 5-day average. This drop in trading activity indicates a lack of interest from investors, contributing to the stock's falling momentum. <BR><BR>While the current price shows a slight increase, the overall trend and performance metrics suggest that Transgene Biotek Ltd is facing challenges that are leading to a decline in its stock value.

When is the next results date for Transgene Biotek Ltd?

The next results date for Transgene Biotek Ltd is 13 February 2026.

The next results date for Transgene Biotek Ltd is scheduled for 13 February 2026.

How has been the historical performance of Transgene Biotek?

Transgene Biotek has seen a rise in net sales from 0.06 Cr in Mar'23 to 0.26 Cr in Mar'25, but continues to report negative operating profits, with a loss of -1.13 Cr in Mar'25 and increasing total expenditures of 1.39 Cr. The company faces ongoing financial challenges, reflected in persistent losses before and after tax, and stagnant cash flow from operations.

Answer:<BR>The historical performance of Transgene Biotek shows a gradual increase in net sales, rising from 0.06 Cr in Mar'23 to 0.26 Cr in Mar'25. However, the company has consistently reported negative operating profits, with an operating profit of -1.13 Cr in Mar'25, indicating a worsening trend compared to -0.62 Cr in Mar'24. The total expenditure has also increased significantly, reaching 1.39 Cr in Mar'25 from 0.85 Cr in Mar'24. The profit before tax has remained negative, with a loss of -0.68 Cr in Mar'25, slightly worse than -0.66 Cr in Mar'24. The net profit after tax also reflects this trend, showing a loss of -0.68 Cr in Mar'25 compared to -0.66 Cr in Mar'24. The company's total liabilities have remained relatively stable at 142.33 Cr in Mar'24, down from 142.36 Cr in Mar'23. The cash flow from operating activities has been stagnant, with no cash inflow reported in recent years.<BR><BR>Breakdown:<BR>Transgene Biotek's financial performance reveals a mixed picture over the years. Net sales have shown a positive trend, increasing from 0.06 Cr in Mar'23 to 0.26 Cr in Mar'25, yet the company continues to face significant challenges with operating profits, which have remained negative, culminating in -1.13 Cr in Mar'25. The total expenditure has escalated to 1.39 Cr, contributing to a profit before tax of -0.68 Cr in Mar'25, indicating persistent financial strain. The net profit after tax mirrors this situation, with a loss of -0.68 Cr. Despite a stable total liability figure of 142.33 Cr in Mar'24, the company's cash flow from operations has not improved, reflecting ongoing operational difficulties. Overall, while there is a slight increase in sales, the underlying profitability issues and rising expenditures suggest that Transgene Biotek is still navigating a challenging financial landscape.

Who are the top shareholders of the Transgene Biotek?

The top shareholder of Transgene Biotek is Dr. K Koteswara Rao, holding 21.89% of shares, while individual investors collectively own 71.88%. There are no institutional shareholders, mutual fund schemes, or pledged promoter holdings.

The top shareholders of Transgene Biotek include Dr. K Koteswara Rao, who holds the largest share at 21.89%. The majority of the company's shares are held by individual investors, accounting for 71.88% of the total holdings. There are no institutional shareholders or mutual fund schemes involved, and there are no pledged promoter holdings. The highest public shareholder is categorized as "Other Shr Off Family," but they hold 0%. Overall, the shareholding structure indicates a strong presence of individual investors in the company.

Who are in the management team of Transgene Biotek?

As of March 2022, the management team of Transgene Biotek includes K Koteswara Rao (Chairman & Managing Director), Ankita Jain (Company Secretary & Compliance Officer), and independent directors Sujana Kadiam, Santosh Kumar, and Marri Swetha.

As of March 2022, the management team of Transgene Biotek includes the following individuals:<BR><BR>1. Sujana Kadiam - Independent Director<BR>2. Ankita Jain - Company Secretary & Compliance Officer<BR>3. Santosh Kumar - Independent Director<BR>4. K Koteswara Rao - Chairman & Managing Director<BR>5. Marri Swetha - Independent Director<BR><BR>These members play various roles in overseeing the company's operations and governance.

Is Transgene Biotek overvalued or undervalued?

As of April 25, 2023, Transgene Biotek is considered risky and overvalued, with a PE ratio of -30.23 and a year-to-date return of -42.61%, significantly underperforming compared to peers and the Sensex.

As of 25 April 2023, the valuation grade for Transgene Biotek has moved from does not qualify to risky. The company is currently assessed as overvalued. Key ratios include a PE ratio of -30.23, an EV to EBITDA of -39.71, and a Price to Book Value of 3.01. In comparison to peers, Max Healthcare has a PE ratio of 100.29, while Apollo Hospitals stands at 69.03, indicating that Transgene Biotek's valuation metrics are significantly weaker.<BR><BR>The company's recent performance has also been disappointing, with a year-to-date return of -42.61%, contrasting sharply with the Sensex's gain of 5.58% over the same period. This underperformance, coupled with negative returns over various time frames, reinforces the conclusion that Transgene Biotek is overvalued in the current market environment.

What is the technical trend for Transgene Biotek?

As of May 14, 2025, Transgene Biotek's technical trend is mildly bearish, with mixed signals across various indicators showing a shift from bearish to mildly bullish on the weekly timeframe, while remaining bearish on the monthly.

As of 14 May 2025, the technical trend for Transgene Biotek has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The daily moving averages are showing a mildly bearish trend, and the Bollinger Bands are sideways on the weekly chart but bearish on the monthly. The KST is mildly bullish weekly but mildly bearish monthly, and Dow Theory shows a mildly bullish trend on the weekly timeframe with no trend on the monthly. Overall, the current technical stance is mildly bearish, driven by the mixed signals across different time frames and indicators.

how big is Transgene Biotek?

As of Jun 06, Transgene Biotek Ltd has a market capitalization of 30.00 Cr, classifying it as a Micro Cap company, with recent net sales of 0.27 Cr and a net profit of -0.67 Cr over the last four quarters. Shareholder's funds are reported at 10.71 Cr, with total assets of 142.33 Cr as of the latest annual period ending Mar'24.

Market Cap: As of Jun 06, Transgene Biotek Ltd has a market capitalization of 30.00 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes Mar'25, Dec'24, Sep'24, and Jun'24, is 0.27 Cr. The sum of Net Profit for the same quarters is -0.67 Cr. This data is presented on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: This is Consolidated data for the latest annual period ending Mar'24. Shareholder's Funds are reported at 10.71 Cr, and Total Assets amount to 142.33 Cr.

What does Transgene Biotek do?

Transgene Biotek Ltd is a biotechnology company focused on developing diagnostic kits, vaccines, oncology solutions, and drug delivery technologies. As of March 2025, it reported net sales of 0 Cr and a net profit of -1 Cr, with a market cap of Rs 30 Cr.

Overview: <BR>Transgene Biotek Ltd is a biotechnology company engaged in research and development in the healthcare services industry, specifically focusing on diagnostic kits, vaccines, oncology, and new drug delivery technologies. It operates within the micro-cap market segment.<BR><BR>History: <BR>Transgene Biotek Ltd was founded in March 1990 by Dr. Koteswara Rao. Initially, the company manufactured and sold diagnostic kits but later transitioned to biotechnology research. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -1 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 30 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 54 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 1.42 <BR>Return on Equity: -6.68% <BR>Price to Book: 2.96<BR><BR>Contact Details: <BR>Address: Plot No 69 & 70 IDA Bollaram, Sangareddy Telangana: 502325 <BR>Website: http://www.transgenebiotek.com

Has Transgene Biotek declared dividend?

No Dividend History Available

Who are the peers of the Transgene Biotek?

Transgene Biotek's peers include Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnostics, and others. Poly Medicure has the highest 1-year return at 24.17%, while Transgene Biotek's return is -33.00%.

Peers: The peers of Transgene Biotek are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Samsrita Labs, Shree Pacetronix, Adeshwar Meditex, and Family Care.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., and Shree Pacetronix, and the rest. Average management risk is noted at Family Care, while Below Average management risk is seen at Adeshwar Meditex. The peers with Growth ratings of Excellent are none, while Average growth is found at Poly Medicure and Indegene, and the rest. Below Average growth is observed at Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., and the rest, while Transgene Biotek and Samsrita Labs do not qualify. Capital Structure ratings are Excellent for Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., and Family Care, while Good is noted at Shree Pacetronix, and Below Average at Adeshwar Meditex.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Poly Medicure at 24.17%, while the lowest is Shree Pacetronix at -60.83%. Transgene Biotek's own 1-year return is -33.00%, which is higher than Shree Pacetronix but lower than Poly Medicure. Additionally, the peers with negative six-month returns include Syngene Intl., Poly Medicure, Vijaya Diagnost., Shree Pacetronix, Family Care, and Chennai Meena.